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Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1
Infection in Patients Treated with Daclatasvir, Peginterferon, and
Ribavirin
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University, Hiroshima, Japand; Radiation Research Center for Frontier Science, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima,
Japane; Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USAf
Direct-acting antivirals (DAAs) are either part of the current standard of care or are in advanced clinical development for the
treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1, but concern exists with respect to the pa-
tients who fail these regimens with emergent drug-resistant variants. In the present study, ultradeep sequencing was performed
to analyze resistance to daclatasvir (DCV), which is a highly selective nonstructural protein 5A (NS5A) inhibitor. Eight patients
with HCV genotype 1b, who were either treatment naive or prior nonresponders to pegylated interferon plus ribavirin (Rebetol;
Schering-Plough) (PEG-IFN/RBV) therapy, were treated with DCV combined with PEG-IFN alpha-2b (Pegintron; Schering-
Plough, Kenilworth, NJ) and RBV. To identify the cause of viral breakthrough, the preexistence and emergence of DCV-resistant
variants at NS5A amino acids were analyzed by ultradeep sequencing. Sustained virological response (SVR) was achieved in 6 of
8 patients (75%), with viral breakthrough occurring in the other 2 patients (25%). DCV-resistant variant Y93H preexisted as a
minor population at higher frequencies (0.1% to 0.5%) in patients who achieved SVR. In patients with viral breakthrough, DCV-
resistant variant mixtures emerged at NS5A-31 over time that persisted posttreatment with Y93H. Although enrichment of
DCV-resistant variants was detected, the preexistence of a minor population of the variant did not appear to be associated with
virologic response in patients treated with DCV/PEG-IFN/RBV. Ultradeep sequencing results shed light on the complexity of
DCV-resistant quasispecies emerging over time, suggesting that multiple resistance pathways are possible within a patient who
does not rapidly respond to a DCV-containing regimen. (This study has been registered at ClinicalTrials.gov under registration
no. NCT01016912.)
Chronic hepatitis C virus (HCV) infection is one of the mostserious global health problems preceding development of
chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC)
(1, 2, 3, 4, 5). To prevent the development of advanced liver dis-
ease, includingHCC, pegylated interferon (PEG-IFN)-based ther-
apies have been administered to patients with chronic HCV infec-
tion. Eradication ofHCVusing PEG-IFN combinedwith ribavirin
(Rebetol; Schering-Plough) (PEG-IFN/RBV) has been shown to
result in remarkable biochemical and histological improvements
in the liver (6, 7). However, patients infected with HCV genotype
1 have experienced a poor response to this therapy as observed by
sustained virological response (SVR) rates of only 40% to 50% (8,
9, 10). Recently, new antiviral agents targeting theHCVnonstruc-
tural protein 3/4A (NS3/4A) protease activity, telaprevir (TVR)
and simeprevir, were approved in several countries as an add-on
to PEG-IFN and RBV (triple therapy) for treating patients in-
fected with HCV genotype 1. The triple therapy significantly im-
proved SVR rates in this patient population (11, 12). However,
many severe adverse effects such as skin rash, anemia, and renal
dysfunction have been reported which often prevent successful
continuation of this triple therapy (12).
To improve safety and effectiveness of anti-HCV therapy, a
number of selective inhibitors targeting HCV proteins, otherwise
known as direct-acting antivirals (DAAs), are currently under de-
velopment. Daclatasvir (DCV; BMS-790052) is a first-in-class,
highly selective nonstructural protein 5A (NS5A) inhibitor with
picomolar potency and broad genotypic coverage (13, 14, 15).
NS5A is an RNA binding multifunctional viral protein and is es-
sential for viral proliferation by interacting with other HCV non-
structural proteins and cellular proteins (16, 17, 18). In a phase 2a
study, a higher SVR rate was observed by adding DCV to the
PEG-IFN alpha-2a plus RBV regimen (19).
Although DAAs are expected to improve the antiviral effect of
PEG-IFN/RBV against HCV genotype 1, drug resistance is still
considered a concern. Emergence of drug resistance is often asso-
ciated with viral rebound and subsequent virologic failure. In the
case of theDCVNS5A inhibitor, the emergence of substitutions at
the NS5A drug target has been reported (19). In patients infected
with HCV genotype 1, one of the most predominant genotypes in
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the world, NS5A amino acid (aa) positions 31 and 93 have been
shown to be susceptible to substitution or enrichment (19). Dou-
ble-amino-acid substitutions in the NS5A region, such as L31M
(substitution from leucine to methionine) plus Y93H (from
tyrosine to histidine) or L31V (leucine to valine) plus Y93H, con-
ferred high resistance to DCV in an in vitro HCV replication sys-
tem (19).
Recently, ultradeep sequencing has been used as a sensitive
technique for characterizing resistance variants (20, 21, 22, 23). In
the present study, ultradeep sequencing was performed using sera
from 8 Japanese chronic hepatitis C patients who participated in a
clinical phase 2a trial using DCV, PEG-IFN alpha-2b (Pegintron;
Schering-Plough, Kenilworth, NJ), and RBV to analyze the asso-
ciation between preexisting DCV-resistant variants and clinical
antiviral responses.
MATERIALS AND METHODS
Study design. This study was a phase 2a, double-blind, placebo-con-
trolled trial (clinicaltrials.gov identifier NCT01016912) for evaluating the
antiviral activity and safety of DCV combined with PEG-IFN alpha-2b
and RBV in treatment-naive patients and nonresponders to the standard
of care with HCV genotype 1. Written informed consent was obtained
from all patients. The study was approved by institutional review boards
at each site and conducted in compliancewith theDeclaration ofHelsinki,
good clinical practice guidelines, and local regulatory requirements.
Patients. Ten patients who met the following inclusion and exclusion
criteria participated in the clinical trial. However, twowere excluded from
the following analysis because they were assigned to a placebo cohort
group and treated with PEG-IFN plus RBV combination therapy without
DCV. Inclusion and exclusion criteria for this clinical trial used the fol-
lowing parameters. (i) The patient age was between 20 and 75 years. (ii)
The patients had been infectedwithHCVgenotype 1 for at least 6months,
and the serumHCVRNA level was105 IU/ml. (iii) Eligible patients had
had no evidence of cirrhosis diagnosed by laparoscopy, imaging, or liver
biopsy analysis within 2 years. (iv) Eligible patients consisted of three
groups: (a) treatment-naive patientswith nohistory of anti-HCV therapy,
including interferon therapy; (b) null responders who had failed to
achieve a 2 log10 HCV-RNA decrease in previous interferon therapy last-
ing 12 weeks or longer; and (c) partial responders who had failed to
achieved undetectable RNA but had achieved a greater than 2 log10 HCV-
RNA decrease in previous interferon therapy lasting 12 weeks or longer.
(iv) The patients had no history of hepatocellular carcinoma, coinfection
with hepatitis B virus or human immunodeficiency virus, other chronic
liver disease, or evidence of hepatic decompensation. (vi) Patients were
also excluded if they had other severe or unstable conditions or evidence
of organ dysfunction in excess of that consistent with the age of the pa-
tient, were unable to tolerate interferon and oral medication or had con-
ditions that could impact absorption of the study drug, or had been ex-
posed to any investigational drug within 4 weeks of study participation or
had any previous exposure to inhibitors of NS5A. (vii) Laboratory find-
ings that excluded participationwere alanine aminotransferase (ALT) 5
times the upper limit of normal (ULN); total bilirubin 2 mg/dl; direct
bilirubin  1.5 ULN; international normalized ratio of prothrombin
time  1.7; albumin  3.5 g/dl; hemoglobin  9.0 g/dl; white blood
cells  1,500/mm3; absolute neutrophil count  750/mm3; platelets 
50,000/mm3; or creatinine 1.8 ULN.
Treatment protocol. All patients received a combination of DCV,
PEG-IFN alpha-2b, and RBV for 24 weeks. Patients subcutaneously re-
ceived PEG-IFN alpha-2b at a dosage of 1.5 mg/kg of body weight/week
and were administered ribavirin orally according to their body weight
(600 mg for  60 kg, 800 mg for 60 to 80 kg, 1,000 mg for 80 kg).
Patients were randomly assigned to receive DCV at 10 mg or 60 mg once
daily for 24 weeks. DCV was provided by Bristol-Myers Squibb, which
conducted this clinical trial. When viral breakthrough occurred, treat-
ment was discontinued with the patient’s consent.
Determination of IL28B genotypes. The IL28B SNP genotype
(rs8099917)was determined usingTaqManpredesigned single nucleotide
polymorphism (SNP) genotyping assays as described previously (24).
Assessment of virological responses.Plasmawas collected at baseline
and at the following fixed time points: weeks 1, 2, 4, 6, 8, and 12 and then
every 4 weeks during treatment. HCV RNA was determined at a central
laboratory using a Roche Cobas TaqMan HCV Auto assay (Roche Diag-
nostics KK, Tokyo, Japan) (lower limit of quantitation [LLOQ], 15 IU/
ml). Sustained viral response (SVR) occurred if HCV RNA became con-
tinuously undetectable by qualitative PCR assay and ALT levels
normalized for 24 weeks after the end of treatment. Viral breakthrough
was defined as an increase of1 log10 IU/ml from nadir at more than one
time point or HCV RNA 15 IU/ml after declining to below that level.
Detection of drug-resistant substitutions by ultradeep sequencing.
HCV RNA was extracted from serum samples by Sepa Gene RV-R
(Sankojunyaku, Tokyo), and the reverse-transcriptase reaction was per-
formed using a random primer and Moloney murine leukemia virus
(MMLV) reverse transcriptase. Briefly, the NS5A region in HCV genome
was amplified by nested PCR using the specific primers 5=-TGGCTCCA
GTCCAAACTCCT G-3=, 5=-GGGAATGTTCCATGCCACGTG-3=, 5=-T
GGAACATTCCCCATCAACGC-3=, and 5=-CCAACCAGGTACTGATT
GAGC-3=, and the amplified fragment distributions were assessed using
an Agilent BioAnalyzer 2100 platform. The fragments were modified by
the use of aMultiplexing Sample Preparation kit (Illumina), and sequence
analysis was performed by the use of a Illumina Genome Analyzer. Imag-
ing analysis and base calling were performed using Illumina Pipeline soft-
ware with default settings as previously reported (20). The N-terminal
domain of NS5A, which includes L31 and Y93, was analyzed. This tech-
nique revealed an average coverage depth of over 1,000 sequence reads per
base pair in the unique regions of the genome. Read mapping to a refer-
TABLE 1 Clinical characteristics of 8 patients treated with combination therapy with daclatasvir, PEG-IFN alpha-2b, and RBV for 24 weeks against
chronic HCV genotype 1b infectiona
Case Age (yr) Sex
Previous interferon
treatment IL28B
HCV RNA
(log IU/ml)
No. of platelets
(103/l)
Hepatic fibrosis
stage
DCV
(mg/day) Efficacy
1 67 F Naive TT 7.1 262 ND 60 SVR
2 42 F Partial TG 5.5 146 F2 60 SVR
3 55 F Naive TT 5.1 181 F2 60 SVR
4 61 M Naive TT 7.1 225 F1 60 SVR
5 39 F Naive TG 6.4 207 F1 10 SVR
6 59 M Partial TG 7.1 178 F2 10 SVR
7 59 F Null TG 7.6 158 ND 10 Breakthrough
8 70 F Null GG 7.0 167 F2 60 Breakthrough
a IL28B, rs8099917 genotype; DCV, daclatasvir; M, male; F, female; SVR, sustained virological response; Partial, partial responder; Null, null responder; ND, not determined. The
hepatic fibrosis stage was determined by liver biopsy analysis according to New Inuyama Classification as follows: F1, fibrous portal expansion; F2, bridging fibrosis.
Murakami et al.
2106 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 June 25, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
ence sequence was performed using Bowtie (25). Because of the short
36-nucleotide read length, mapping hypervariable regions with multiple
closely spaced variants against a reference sequence yields poor coverage.
Alternative reference sequences were included to improve coverage in
variable regions.
RESULTS
Characteristics of patients and treatment efficacy.Eight patients
were treated with DCV, PEG-IFN alpha-2b, and RBV triple ther-
apy. To compare dosing effects of DCV, 3 patients were adminis-
tered 10 mg/day of DCV and the remaining 5 patients were ad-
ministered 60 mg/day of DCV. As shown in Table 1, subjects
included 2 males and 6 females, with a median age of 59. All
subjects were infected with HCV genotype 1b. SVR was achieved
in 6 of 8 patients (75%), and viral breakthrough occurred in the
remaining 2 patients (25%).
Detection of drug-resistant HCV variants prior triple ther-
apy. To analyze the differences in antiviral effects, ultradeep se-
quencing was performed on pretreatment serum samples from 7
of the 8 patients; sample from patient case 3 was not assessed. To
account for errors introduced by RT-PCR as well as errors inher-
ent in the PCR technology as reported (26), we used a minimum
variant frequency threshold of 0.1% of the total reads, referring
to our basal experiments using a HCV-expressing plasmid as a
control (Table 2). At aa 31 in NS5A, 866,032 reads (496,711 to
1,432,680) on average were obtained, and no significant DCV-
resistant variants were detected in any of the 7 patient samples
examined (Table 3). At NS5A aa 93, 154,093 reads (49,349 to
289,481) on average were obtained, and DCV-resistant variants
(Y93H) were detected in 4 patients (cases 1, 2, 4, and 5). Other
NS5A regions relating to low resistance, including aa 28, aa 30, aa
32, and aa 92, were also analyzed prior to the treatment. The pre-
existence of these amino acid substitutions was less related to
treatment efficacy (Table 3).
Virological response.The serumHCVRNA titers in 6 patients
(cases 1 to 6) who achieved SVR are shown in Fig. 1. In cases 1, 2,
4, and 5, despite the presence of DCV-resistant variants (Y93H),
serum HCV RNA levels were below the detectable limit between
weeks 1 and 4 of treatment and remained undetectable, resulting
in the patients achieving SVR. In contrast, the serum HCV RNA
titers of 2 patients (cases 7 and 8) rebounded at week 4 or 6 of
treatment and returned to pretreatment levels (Fig. 2A and 3A).
Interestingly, no significant DCV-resistant variants were detected
prior to treatment in these 2 patients.
To analyze the mechanism of viral breakthrough, ultradeep
sequencing of the NS5A N-terminal region was performed using
patient sera at several time points, and the percentages of drug-
TABLE 2 Threshold assessment introduced by error in ultradeep
sequencing analysis at NS5A amino acids 31 and 93, determined by a
basal experiment using a wild-type HCV-expressing plasmid as a
controla
Position
Total no. of
reads Frequencies (%)
Error rate
(%)
aa 31 1,284,644 L (99.27), S/F/V (0.073) 0.073
aa 93 512,323 Y (99.44), H/C (0.056) 0.056
a Substituted amino acids are shown by standard single-letter codes. Amino acid
substitutions were defined as those occurring at a rate of more than 0.1% among the
total reads. This frequency is expected to be sufficient to overcome the error threshold
of the sequencing platform used in this study.
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resistant variants at aa 31 and aa 93 were compared. In case 7,
according to the results of ultradeep sequencing, 100%of the total
reads showed a wild-type amino acid sequence (leucine) at aa 31,
and 100% of the total reads showed the wild type (tyrosine) at aa
93 before the treatment (Fig. 2B). However, the proportion of the
wild type at aa 31 at week 10 of treatment was predominantly
replaced by DCV-resistant variants L31I (92.8%) and L31M
(4.9%), and enrichment of the L31I and L31M variants was ob-
served during triple therapy. The level of detection of these vari-
ants was maintained 16 weeks after the end of treatment. In addi-
tion, although a variant at aa 93 could not be identified before
treatment, the Y93H variant also appeared (32.5%) at week 10 of
treatment. The Y93H variant, which is known to be associated
with DCV resistance, persisted (32.5%) 16 weeks after the end of
treatment.
In patient case 8, DCV-resistant variants were not detected
prior to treatment (Table 3). Surprisingly, L31V and L31M were
rapidly enriched and comprised more than 98% of the clonal se-
quences at week 1 of treatment (Fig. 3B). At the same time, the
Y93H variant also started to outgrow the wild-type sequence and
was detected in up to 35.5% of the sequences during the course of
therapy. The proportions of resistance variants at aa 31 and aa 93
did not decrease after discontinuation of the therapy and persisted
at similar levels 16 weeks after the end of therapy.
According to these results, viral breakthrough was induced by
the selection ofDCV-resistant variants that included substitutions
at L31I/V/M and Y93H. These DCV-resistant variants persisted at
high frequency after discontinuation of the triple therapy.
DISCUSSION
Treatment of chronic hepatitis C has drastically improved since
the introduction of PEG-IFN and RBV combination therapy.
However, only approximately 40% to 50% of patients infected
with a high titer of HCV genotype 1 are able to achieve SVR (27).
To improve the effectiveness of anti-HCV therapy, a number of
DAAs targeting HCV-related proteins, such as NS3/4A protease
or NS5B polymerase, are under development. DCV is one of the
DAAs under development and is a first-in-class NS5A inhibitor
with picomolar potency and broad genotypic coverage (13, 14,
15). In a proof-of-concept clinical study, 90% of patients with
HCV genotype 1b infection treated with the dual oral combina-
tion of DCV plus asunaprevir achieved SVR (28, 29, 30). Based on
these reports, DCV is expected to be a specific agent against
chronic hepatitis C. In the present study, triple therapy using
DCV, PEG-IFN alpha-2b, and RBV was administered to patients
with HCV genotype 1b infection. As shown in Table 1, all patients
hadHCVRNA titers 5 log10 IU/ml, 5 of 8 patients had unfavor-
able IL28B (rs8099917) genotypes (TG or GG), and 4 of 8 patients
were prior partial or null responders to previous treatment with
PEG-IFN plus RBV combination therapy. Based on this clinical
background, the study patients were predicted to be difficult to
treat using conventional PEG-IFN plus RBV combination ther-
apy. However, HCV RNA titers reduced rapidly with the DCV
triple therapy, and 75% of patients were able to achieve SVR.
Although these clinical results were obtained froma small number
of subjects in the clinical trial and at one hospital, these results
suggest that DCV is likely to improve the outcome of the anti-
HCV treatment in combination with PEG-IFN plus RBV therapy.
Resistance has been shown to emerge with different classes of
DAA regimens. The reason that treatment of some of these pa-
tients fails, however, remains unclear. Prior to antiviral treatment
with DAAs, amino acid substitutions in HCV-related proteins
that confer resistance to DAAs can preexist. Enrichment of vari-
ants during therapy has been reported, although monitoring the
changes using ultradeep sequencing is not so common. HCV is an
error-prone RNA virus where mutations frequently occur
throughout theHCVgenome (31, 32, 33), anddrug-resistant vari-
ants are sometimes present as a minor population in patients who
have never been treated with DAAs (34). Of the sequenced HCV
clones, samples frompatient cases 1, 2, 4, and 5 hadDCV-resistant
variants at frequencies ranging from 0.1% to 0.5% (Table 3). In-
terestingly, viral breakthrough did not occur during triple therapy
in these cases despite the preexistence of a higher proportion of
DCV-resistant variants. Viral breakthrough occurred in patient
cases 7 and 8, where drug-resistant variants had not been detected
prior to treatments. Consequently, several clinical factors were
compared to identify additional factors that may be associated
with viral breakthrough. There were no differences in HCV RNA
FIG 1 PlasmaHCVRNA levels of 6 patients who achieved SVRduring combination therapywith daclatasvir, PEG-IFN alpha-2b, andRBV for 24weeks followed
by 24 weeks posttreatment. LLQ, lower limit of quantitation (15 IU/ml).
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levels or baseline clinical characteristics (Table 1). However, the
two patients with viral breakthrough both had unfavorable IL28B
genotypes (TGorGG) andwere null responders to prior PEG-IFN
plus RBV combination therapy. In previous studies using a hu-
man hepatocyte chimeric mice model, TVR-resistant populations
remained highly susceptible to IFN treatment (20). Since the two
patients experiencing viral breakthrough in this study were prior
null responders to IFN, there is a possibility that they could re-
spond to a quadruple therapy using IFN as a component of the
treatment. Patient cases 1, 2, 4, and 5 achieved SVR despite the
detection of higher proportions of DCV-resistant variants before
treatment initiation with DCV, PEG-IFN, and RBV. It is possible
that the preexistence of DCV-resistant variants might have a
greater impact on virologic response in patients considered to be
refractory to IFN, such as those with a poor response to previous
IFN therapy, although that could not be concluded from this
study given that the 2 failures had no significant DCV-resistant
variants before treatment.
Recent studies have demonstrated that levels of enriched drug-
resistant variants gradually decline after DAA treatment is discon-
tinued and that most HCV variants are eventually replaced by
baseline sequence posttreatment (20). In patient case 7, although
DCV-resistant variants had not been detected prior treatment,
more than 90% of HCV sequences were replaced by sequences
encoding L31I/M and Y93H at week 10 of therapy. These drug-
resistant variants were still detected at high proportions 16 weeks
after cessation of treatment. Similarly, in patient case 8,more than
99% of HCV sequences had already been replaced by the L31I/
FIG 2 Clinical course of case 7 with viral breakthrough during combination therapy. (A) PlasmaHCVRNA levels. (B) Time course of the amino acid frequency
at L31 and Y93 in the NS5A region by ultradeep sequencing. WT, wild type; LLQ, lower limit of quantitation (15 IU/ml).
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V/M variant at week 1, and a high proportion of these variants
persisted until the last posttreatment time point, 16 weeks after
treatment. These results suggest that drug-resistant variants can
be rapidly enriched during the early phase of DAA therapy. Be-
cause ultradeep sequencing using this Illumina technology yields
only 36 nucleotide fragments, it is not clear whether or not the
mutations that encode the L31IM/V and Y93H substitutions exist
in the same genomic RNA strand. However, based on the fre-
quency of themutations, at least some of these are likely to exist on
the same genomic RNA strand. Only 8 patients could be assessed
in this study; however, rapid selection of DAA-resistant variants
during combination treatment has been previously observed (20).
Interestingly, both patient 7 and patient 8 had higher viral loads at
week 1 of treatment (1,000 IU/ml) than the other patients
within the group. Viral load response at week 1 may therefore be
more of a predictor of the emergence of resistance and virologic
outcome than preexisting minor populations of NS5A resistance-
associated polymorphisms.
Ultradeep sequencing analysis revealed that the DCV-resistant
variants were maintained at a high frequency after cessation of the
treatment. It has been reported that drug-resistant variants have re-
duced replication capacity and are easily replaced by the wild type
(20). However, the present results, in agreement with other studies
(19), suggest that NS5A aa 31 or aa 93 resistance variants are fit and
possibly comparable to the wild type in fitness. With respect to viral
fitness, a L31M/V plus Y93H double-substitution variant was re-
ported to reduce DCV susceptibility (4,227/8,336-fold change, re-
spectively) with impaired replication (36%/30% per the wild type,
respectively) in the HCV genotype 1b replicon (35). Although it was
reported that second-site replacements at NS5A restore efficient rep-
lication in HCV genotype 2a in vitro (13), there is not sufficient evi-
dence about third-site replacements atNS5A that can restore replica-
FIG 3 Clinical course of case 8 with viral breakthrough during combination therapy. (A) PlasmaHCVRNA levels. (B) Time course of the amino acid frequency
at L31 and Y93 in the NS5A region by ultradeep sequencing. LLQ, lower limit of quantitation (15 IU/ml).
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tion of L31 plus Y93 double-substituted variants in HCV genotype
1b. Long-term follow-up of these NS5A variants is required to fully
understand their fitness versus that of the wild-type sequence.
There are several limitations in this study based on the use of
ultradeep sequencing and 36-nucleotide-read-length fragments
without being able to examine linkages with other viral domains.
Further analysis using ultradeep sequence technologies with lon-
ger read lengths is needed to clarify the relationship betweenmul-
tiple substitutions and treatment response.
In conclusion, 8 patients withHCV genotype 1b infectionwere
treated with DCV, PEG-IFN alpha-2b, and RBV triple therapy.
This treatment is expected to improve the SVR rate greatly, but
viral breakthroughmight develop in some patients with the emer-
gence of DCV-resistant variants. In this study, preexisting DCV-
resistant variants had no effect on the results of DCV plus PEG-
IFN and RBV treatment. Ultradeep sequence analysis of
preexisting DCV variants is not useful to predict the response to
combination treatment; however, it might be useful to detect the
early emergence of resistant variants. A larger-scale study would
be required to establish the methods for the early detection of
DCV-resistant variants during treatment with DCV-containing
regimens. It is expected that in the near future, DAAs will be pref-
erentially used for the treatment of chronicHCV infection. There-
fore, it is important to devise strategies for preventing the emer-
gence and selection of DAA-resistant variants and suppress the
replication of preexisting DAA-resistant viral populations.
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